Biofilms: Biofilm Composition as a Predictive Biomarker for Prosthetic Joint Infection

Sponsor
Portsmouth Hospitals NHS Trust (Other)
Overall Status
Completed
CT.gov ID
NCT05804058
Collaborator
University of Portsmouth (Other)
35
1
18.7
1.9

Study Details

Study Description

Brief Summary

Prosthetic joint infection (PJI) represents one of the most common reasons for failure among hip and knee prostheses, with an incidence of around 1-2%. Infection can occur early (within days of surgery) or late (over a year after surgery), and no specific early markers for infection onset exist. Given the significant costs to the NHS for corrective revision surgery, the added suffering and risk to patients from surgery, and the risk of enhancing antimicrobial resistance through the use of broad-spectrum antibiotics, a more specific predictive test for early onset of infection is required.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Revision surgery

Detailed Description

Over 80% of human infection is estimated to be a result of biofilm formation. Biofilms are an accumulation of microorganisms (predominantly bacteria) on a surface, resulting in a functional community which provides antibiotic resistance and a beneficial environment for the growth of pathogenic species that would otherwise be removed by the body's defences.

The use of medical implants in modern medicine has become an increasingly common occurrence, with hip and knee arthroplasty accounting for a large number of medical implant surgeries. Unfortunately, infections frequently result in failure of the implanted device (around 1-2% for knee and hip arthroplasty), requiring extensive revision surgery. Currently, no predictive biomarkers for PJI exist, and diagnostic tests require infection to have already taken hold and may often be highly invasive. Research conducted by the NIH suggests that accumulation of bacteria (known as biofilms) may account for over 80% of microbial infections in the human body and have been shown to develop on medical implants, such as those used in hip and knee arthroplasty. Bacterial biofilms on medical implants are poorly understood, making treatment very complex.

The investigators aim to identify early predictive biomarkers for PJI based on assessment of the biofilm structure on implants removed in revision surgery, either as a result of PJI or due to aseptic causes such as mechanical failure. The investigators will explore biofilm formation on hip joint prostheses using next generation sequencing (NGS) and 3D phase-contrast X-ray microscopy, and will compare bacterial diversity and biofilm structure between infected and non-infected samples to answer three main questions:

  1. Can The investigators accurately describe the characteristic microbiome of hip joint prosthetic biofilms?

  2. Is there a distinct characteristic microbiome or biofilm structure associated with PJI?

  3. Can The investigators detect such characteristic biofilm members as biomarkers in simple blood tests?

Study Design

Study Type:
Observational
Actual Enrollment :
35 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Assessment of Biofilm Composition as a Predictive Biomarker for Prosthetic Joint Infection
Actual Study Start Date :
Jul 1, 2019
Actual Primary Completion Date :
Jan 19, 2021
Actual Study Completion Date :
Jan 19, 2021

Arms and Interventions

Arm Intervention/Treatment
Orthopaedic Patients

Patients due to undergo prosthetic hip revision surgery

Procedure: Revision surgery
Patients due to undergo prosthetic revision surgery for any reason (infection or aseptic)

Outcome Measures

Primary Outcome Measures

  1. Characteristic Formation of bacterial biofilm on orthopaedic implants [1 day study visit]

    measured by infection assessment- this is the term for the measure

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Male or Female, aged 18 years or above.

  • Due to undergo prosthetic revision surgery for any reason identified by the clinical team Willing to provide informed consent

Exclusion Criteria:
  • Participant lacking capacity to give informed consent

  • Any other clinical reason the participant should not be included in the study- at the discretion of the clinical team

Contacts and Locations

Locations

Site City State Country Postal Code
1 Portsmouth Hospitals NHS Trust, Queen Alexandra Hospital Portsmouth Hampshire United Kingdom PO6 3LY

Sponsors and Collaborators

  • Portsmouth Hospitals NHS Trust
  • University of Portsmouth

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Portsmouth Hospitals NHS Trust
ClinicalTrials.gov Identifier:
NCT05804058
Other Study ID Numbers:
  • PHT/2019/31
First Posted:
Apr 7, 2023
Last Update Posted:
Apr 7, 2023
Last Verified:
Apr 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 7, 2023